Integra Lifesciences Raises FY2026 Adj EPS Guidance from $2.30-$2.40 to $2.40-$2.50 vs $2.35 Est; Affirms FY2026 Sales Guidance of $1.662B-$1.702B vs $1.674B Est

Benzinga Newsdesk www.benzinga.com Positive 82.5%

Neg 0% Neu 0% Pos 82.5%

Integra Lifesciences (NASDAQ:IART) raises FY2026 Adj EPS guidance from $2.30-$2.40 to $2.40-$2.50 vs $2.35 analyst estimate. Affirms FY2026 sales outlook from $1.662 billion-$1.702 billion to $1.662 billion-$1.702 billion vs $1.674 billion estimate.